BOULDER, Colo., March 28, 2024 (GLOBE NEWSWIRE) — Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN) is a leading pharmaceutical company focused on the discovery and development of next-generation small-scale therapeutics. A clinical-stage precision oncology company. The molecular kinase inhibitor co-developers will today discuss initial proof-of-concept data for ELVN-001 and the evolving chronic myeloid leukemia (CML) landscape on Thursday, April 11, 2024 at 8:00 a.m. (Eastern Standard Time) to host a webcast. ELVN-001 is a highly selective small molecule kinase inhibitor designed to specifically target the ATP pocket of the BCR-ABL gene fusion, an oncogenic factor in CML patients.
The event will be attended by leading CML researchers and hematology care experts, Professor Michael Mauro of Memorial Sloan Kettering Cancer Center, Professor Fabian Lang of Goethe University Hospital, and the management team of Enliven Therapeutics. . Discussion will address initial proof-of-concept data from Phase 1a of ELVN-001, evolving treatment paradigms in CML, and how ELVN-001 can fit into his CML environment.
This event will be webcast live and can be accessed by visiting the Investor Relations section of our website at https://ir.enliventherapeutics.com/. To attend the live event, please register using this link. An archived webcast will be available after the event ends.
About Enliven Therapeutics
Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule inhibitors that help cancer patients not only live longer, but live better. Enliven aims to address existing and emerging unmet needs with precision oncology approaches that improve survival rates and improve overall health. Enliven's discovery process combines deep insights into clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class treatments. Enliven is based in Boulder, Colorado.
contact:
Investor
ir@enliventherapeutics.com
media
media@enliventherapeutics.com